Introduction
Non-alcoholic fatty liver disease (NAFLD) is the world's most prevalent liver disease [1] . The majority of subjects with NAFLD have a benign course of disease, however some subjects develop non-alcoholic steatohepatitis (NASH) and fibrosis [2, 3] . It is difficult to identify individuals with fibrosis, which can lead to cirrhosis and hepatocellular carcinoma [4, 5] .
The impact of alcohol consumption on NAFLD is controversial. First, the main cause of death in NAFLD is cardiovascular disease [6] , and moderate alcohol consumption has been suggested to reduce the risk of death in cardiovascular disease [7] , why it could be argued that alcohol could be beneficial in NAFLD. Secondly, previous studies have shown an association between low-to-moderate alcohol consumption and lower risk for NAFLD, NASH and fibrosis [8, 9, 10] . Also, regular consumption of moderate amounts of alcohol, 150 ml of red wine per day for 90 days did not induce hepatic steatosis in healthy subjects [11] . However, population-based studies have indicated an interaction on the risk of liver damage between a high body mass index (BMI), which is highly associated with NAFLD [12] , and alcohol consumption [13, 14] .
Previous studies on alcohol consumption in NAFLD have defined alcohol consumption as current consumption, not taking the lifetime amount of alcohol consumption into account. This approach may misclassify subjects with a history of alcohol dependency, who have eventually stopped drinking, as non-drinkers.
Furthermore, most studies have been unable to adjust for potential confounders, including BMI and presence of diabetes. In addition, lifestyle factors such as consumption of soft drinks [15] and coffee [16] as well as physical activity [17] that might have disease-modifying properties, have not been investigated as potential confounders.
The aim of this study was to examine the impact of lifetime alcohol consumption on the severity of fibrosis stage and presence of NASH in NAFLD, after adjusting for potential confounders.
Material and methods
We performed a prospective study of subjects who underwent liver biopsy as part of a NAFLD/NASH severity work-up at five university hospitals in Sweden: Karolinska University Hospital(N=73), Linköping University Hospital (N=26), Sahlgrenska University Hospital (N=4), Uppsala University Hospital (N=9) and Skåne University Hospital (N=8). Other liver diseases were excluded before biopsy in all subjects as part of the routine work-up. Patients who reported consuming more than 14 units of alcohol per week were excluded.
At the occasion of the biopsy, blood was drawn after an overnight fast for biochemical analyses, including markers of glucose metabolism, inflammation, lipid profile and markers of alcohol consumption. Also, a standard oral glucose tolerance test was performed in subjects without known diabetes mellitus. Furthermore, four questionnaires were used, including the lifetime drinking history (LDH) questionnaire [18] , the alcohol-use disorders identification test (AUDIT) questionnaire, a standard screening instrument for detecting risky and harmful alcohol use [19] , a food frequency questionnaire [20] , and a questionnaire grading physical activity, as described below.
Liver biopsies
All biopsies were centrally read by an expert liver pathologist (R.H.), blinded to subject data including the original pathology report, and scored according to the NAFLD Activity Score (NAS) [21] as well as the Steatosis Activity Fibrosis (SAF) system [22] . Presence of NASH was defined according to the fatty liver inhibition of progression (FLIP) algorithm, as the presence of both fat, lobular inflammation and ballooning [23] . Fibrosis stage was scored according to the NASH CRN fibrosis scoring system as 0-4 [21] . Only biopsies with ≥ 7 portal tracts were included in the study.
Alcohol consumption
We used the LDH questionnaire to assess lifetime alcohol consumption. In this tool, subjects report alcohol consumption during different periods of life. For each period, the subject reports the mean number of days per year he or she drank any amount of alcohol, and the mean number of drinks per drinking day. In the same way, binge drinking, defined as drinking equal to or more than five units of alcohol per day is reported. One unit of alcohol as defined in Sweden, containing 12 grams of alcohol [24] , corresponds to 330 ml of beer, 150 ml of wine or 40 ml of spirits. The age at the first consumed alcoholic drink, as well as age at the last consumed alcoholic drink if the subject had stopped drinking is noted. This data was used to calculate the number of drinking years per patient.
Total lifetime consumption of alcohol was calculated and is presented as the median number of drinks per week from the age of onset of alcohol consumption.
Other measures of alcohol consumption included total alcohol consumption during the last year and total alcohol intake during the last week. Also,drinks per drinking day were defined as the median number of drinks per occasion of drinking alcohol.
Gram-years of alcohol consumption were calculated by multiplying the amount of alcohol consumed in grams per day with the number of drinking years.
Relying on self-reported alcohol consumption has the risk of misclassifying subjects who underreport their alcohol intake. One way to control for this is the use of alcohol-related biomarkers. A relatively new biomarker is phosphatidyl ethanol (PEth) [25] . We stratified the cohort on the level of their PEth values, using a cut-off of 0.3 μmol/L as per the manufacturers recommendations to identify subjects consuming more than moderate amounts of alcohol [26] . Subjects with PEth values ≥ 0.3 μmol/L were not evaluated in the primary statistical model, but used in sensitivity analyses and for descriptive statistics. In sensitivity analysis, we used different cutoffs of PEth, 0.1 and 0.2 respectively.
Potential confounding factors
Diabetes mellitus type 2 was defined as previously diagnosed and/or pharmacological treatment for diabetes. In subjects without known diabetes, a standard 75 g oral glucose tolerance test was performed. Subjects with a fasting capillary glucose ≥ 126 mg/dL or with a capillary glucose two hours after the glucose load ≥ 200 mg/dL were classified as having diabetes mellitus type 2. Blood pressure was measured after a five-minute resting period, and arterial hypertension was defined as a pre-existing diagnosis of this, or a finding of a blood pressure of above 140/90 mmHg on two separate occasions. Height and weight as well as hip and waist measurements were recorded without shoes and with light clothing.
Coffee and soft drink servings per week were estimated using a quantitative food frequency questionnaire, measured on a continuous scale. One serving was defined as 200 ml of each beverage. Physical activity during the last year before biopsy was measured using a semi-quantitative questionnaire, where leisure-time physical activity was scored on a scale of 1-6, were 1 indicated very low physical activity and 6 indicated hard aerobic training, performed on a regular basis, at least once per week.
Smoking was classified as if the subject had ever or never been smoking.
Statistical analyses
Differences between continuous variables were analysed using the Mann-Whitney Utest, and between categorical variables using Fischer's Exact test. We applied an ordinal logistic regression model to estimate the effect of alcohol consumption on the stage of fibrosis, and a logistic regression model to estimate the effect of alcohol consumption on the presence of NASH. In a separate model, we divided the cohort into quartiles of weekly alcohol consumption and examined the association with fibrosis stage, using the second quartile of alcohol consumption as the reference category. Data regarding gram-years was analysed dichotomized on the median value.
The multivariate models included lifetime alcohol consumption per drinking week as the primary independent variable, and the full model was adjusted for age at biopsy, diabetes mellitus type 2, arterial hypertension, BMI and smoking status, dichotomized as ever or never. Data are presented as odds ratios (OR) with 95% confidence intervals (CI), with a significance level of 0.05. All analyses were performed using STATA version 12.1 (StataCorp, College Station, Texas, US).
Ethical considerations
The Regional Ethics Committee at Karolinska Institutet approved the study (Dnr 2012/1686-32; 03-Jan-2012), and all subjects gave written informed consent.
Results
Between 2012 and 2015, 139 subjects were identified and gave informed consent.. Furthermore, 13 subjects had a PEth value of ≥ 0.3 μmol/L (median 0.52, range 0.31-1.05), indicating more pronounced recent alcohol consumption than reported at the visit or in the questionnaires; these 13 subjects were evaluated separately in the regression analyses.
Of the 107 subjects with complete data, 20 had fibrosis stage 0, 42 had stage 1, 17 had stage 2, 13 had stage 3 and 15 had stage 4. 65 subjects (61%) had NASH according to the FLIP algorithm [23] . Participant characteristics on the entire cohort are presented in Table 1 , and stratified on the median lifetime alcohol consumption in table 2.
Alcohol consumption
Reported lifetime alcohol consumption was low, with a median lifetime consumption of 1.1 units of alcohol per week (range 0-13.2). Data on patterns of alcohol consumption are presented in table 1, and stratified on the median lifetime alcohol consumption in table 2.
Impact of alcohol consumption on fibrosis stage
Up to a maximum of 13 reported drinks per week, each additional unit in alcohol consumption per week was associated with decreasing odds ratios (OR) for having a 
Impact of potential confounders on fibrosis stage
Neither soft drink consumption, coffee consumption or extent of physical activity was associated with a higher fibrosis stage (data not shown). Adding soft drink and coffee consumption and physical activity to the model did not change the estimates significantly (OR 0.87; 95% CI 0.76-1.00; p=0.05). Crude ORs for all tested potential confounders, and adjusted ORs for covariates included in the final models are presented in Table 3 .
Impact of all variables on presence of NASH
Crude ORs for associations of the study variables with the presence of NASH, as defined by the FLIP algorithm, are presented in Table 4 . No association for any studied lifetime alcohol consumption parameter with NASH was found. 
Blood parameters
Subjects who consumed more than the median amount of 1.1 units of alcohol per week had lower values of inflammatory markers TNF (median 7.9 vs. 9.7 ng/L, p=0.05) and highly sensitive CRP (median 1.5 vs. 2.7 mg/L, p=0.004), but slightly higher values of total cholesterol (193 vs. 170 mg/dL, p=0.03). There were no significant differences in other metabolic markers including HOMA-IR or transaminases (table 2) .
Discussion
This is the hitherto largest study that examines the association of lifetime alcohol consumption with disease severity in NAFLD using the highly detailed LDH questionnaire and adjusting for potential confounding factors. Our main finding was that low to moderate alcohol consumption, up to a maximum of 13 units per week, was associated with lower stages of liver fibrosis, even after adjusting for confounders. The lowest risk for fibrosis was found in the top quartile of lifetime alcohol consumption, consuming 3-13 drinks per week. In contrast, subjects with biochemical signs of more than moderate current alcohol consumption, as indicated by serum PEth levels above the cut-off of 0.3 μmol/L, had almost three-times increased ORs for higher stages of fibrosis (OR 2.77; 95% CI 1.01-7.59; p=0.047), indicating that a high consumption of alcohol increases the risk for fibrosis progression in NAFLD. Of note, PEth is not yet applied internationally as an integral marker of recent alcohol consumption, and has not been used in previous studies on NAFLD. Thus, these thirteen subjects would have been included as unbiased NAFLD cases in any other study not using PEth. In a previous randomized controlled trial, consumption of 150 ml of red wine for women and 300 ml for men per day for three months did not elevate PEth > 0.3 μmol/L in a single subject [27] , indicating that these 13 subjects potentially drank more than these amounts.
Strengths of this study include the size of the cohort, the detailed methodology to define the exposure of lifetime alcohol intake, data on potential confounders and the gold standard diagnosis of biopsy-verified NASH and fibrosis stage, evaluated by a single, blinded specialized liver pathologist. Furthermore, this was a multi-centre study performed in university hospitals where concomitant liver disease was carefully excluded, which is likely to reduce the risk of selection bias and to increase the external validity of the study.
Limitations include the use of retrospective questionnaires to study alcohol consumption, which inevitably infers the risk of bias -especially recall bias.
However, the LDH questionnaire has been validated [28] and shown to have a high test-retest reliability [29] . In addition, removing subjects with a PEth of ≥ 0.3 μmol/L from the statistical models likely reduces bias. Also, the finding of a median consumption of 1.1 units per week is well in line with findings from a representative sample of the general Swedish population, where 92% of women and 85% of men were found to consume less than 21 grams of alcohol per week, roughly equal to 2 units [24] . Conversely, the finding that the subgroup with PEth values of ≥ 0.3 μmol/L had higher ORs for a higher fibrosis stage is well in line with current evidence that more than moderate alcohol consumption is harmful for the liver [30, 31, 32] .
This group of subjects probably underreported their current alcohol intake.
Furthermore, the sample size of the current study was rather small, disallowing us to for example stratify results on sex.
A number of cross-sectional studies has recently reported that low to moderate current alcohol consumption is associated with a lower risk of NAFLD [10] and also of NASH [9] . Dunn et al used the LDH to exclude lifetime drinkers from their nondrinker population, but did not report lifetime drinking data [9] . Only one previous study has used the LDH questionnaire to fully examine the effect of lifetime alcohol consumption on NAFLD severity. Similar to our study, subjects in the study by Kwon et al who consumed more than the median lifetime amount of 24 gram-years of alcohol had lower odds ratio for fibrosis stage 3-4 compared to subjects who consumed less than the median amount [33] . However, in that study, only 77 subjects were included, and alcohol consumption was reported at as low as 23 gram-years, compared to 56 gram-years in our study, which is in line with the normal mean alcohol consumption in Sweden [24] . In addition, we evaluated confounders such as consumption of soft drinks and coffee, but found no association to increased fibrosis or NASH.
In contrast to previous studies [9, 10], we did not find different alcohol consumption patterns between subjects with and without NASH. Alcohol consumption during the last week before biopsy was low in our cohort (median 0 units), which might have blurred a potentially protective effect of low to moderate alcohol consumption on NASH that was observed in other studies [9] . Conversely, subjects with PEth ≥ 0.3 μmol/L had higher NAS, indicating that a current higher than moderate alcohol consumption is associated with a more pronounced disease activity.
This finding suggests a J-like risk profile for alcohol consumption and liver fibrosis, passing from a potentially beneficial to a potentially harmful effect at around 2-3 drinks per day. Interestingly, this is also the pattern for alcohol consumption and mortality. For example, Thun et al found a reduced risk of overall mortality for persons who reported at least one drink per day in 490.000 US adults, and an increased risk of overall mortality for persons consuming more than three drinks per day [7] . In a meta-analysis of the effect of alcohol consumption on cardiovascular disease, the main finding was that the lowest risk for coronary heart disease mortality was seen in subjects drinking 1-2 units of alcohol per day [34] .
Interestingly, subjects who consumed more than the median amount of alcohol (1.1 unit/week) had lower inflammatory markers including TNF and highly sensitive-CRP compared to subjects who consumed less than the median. This might indicate a potential anti-inflammatory potential of alcohol, and is in agreement with a 52% lower risk of developing rheumatoid arthritis for women who consume more than three units of alcohol per week [35] .
We conclude that an alcohol intake of up to 13 units per week is inversely associated with the risk for a higher fibrosis stage, and that high levels of PEth are associated with higher stages of fibrosis in NAFLD.
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